The Vanguard Group, Inc. recently announced the acquisition of new stake in Homology Medicines Inc. (NASDAQ:FIXX). The institutional investor has increased its shareholding in the Healthcare company by 6.14% to 2.03 million shares with purchase of 0.12 million shares. This fresh investment now brings its stake to 3.53% valued currently at $2.55 million. In addition, Geode Capital Management LLC raised its holdings by 930.0 to 0.39 million shares. And Renaissance Technologies LLC has lifted its position by 52.37% or 0.13 million shares – to 0.38 million shares.
With over 72390.0 Homology Medicines Inc. (FIXX) shares trading Tuesday and a closing price of $1.63 on the day, the dollar volume was approximately $0.12 million. The shares have shown a negative half year performance of -32.64% and its price on 01/24/23 lost nearly -1.81%. Currently, there are 57.45M common shares owned by the public and among those 52.23M shares have been available to trade.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 10 analysts who have offered their price forecasts for FIXX have a consensus price objective of $8.14. The analysts have set the share’s price value over the next 12 months at a high of $20.00 and a low of $2.10. The average price target is 79.98% above its recent price level and an upside to the estimated low will see the stock gain 22.38% over that period. But an upside of 91.85% will see the stock hit the forecast high price target while median target price for the stock is $7.50.
Insiders at the company have transacted a total of 15 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 74,910 shares. Insider sales of the common stock occurred on 5 occasions, with total insider shares sold totaling 23,509 shares.
The top 3 mutual fund holders in Homology Medicines Inc. are BB Biotech AG, Vanguard Total Stock Market Index, and JPMorgan Funds – Thematics – Gene. BB Biotech AG owns 1.62 million shares of the company’s stock, all valued at over $2.04 million. The company sold -0.11 million shares recently to bring their total holdings to about 2.82% of the shares outstanding. JPMorgan Funds – Thematics – Gene sold 56050.0 shares to bring its total holdings to over 0.71 million shares at a value of $0.89 million. JPMorgan Funds – Thematics – Gene now owns shares totaling to 1.23% of the shares outstanding.
However, the script later moved the day high at 1.7550, down -1.81%. The company’s stock has a 5-day price change of -2.98% and 13.19% over the past three months. FIXX shares are trading 29.37% year to date (YTD), with the 12-month market performance down to -51.63% lower. It has a 12-month low price of $1.04 and touched a high of $4.26 over the same period. FIXX has an average intraday trading volume of 164.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 13.16%, 8.59%, and -11.47% respectively.
Institutional ownership of Homology Medicines Inc. (NASDAQ: FIXX) shares accounts for 51.50% of the company’s 57.45M shares outstanding. Mutual fund holders own 20.96%, while other institutional holders and individual stakeholders account for 34.63% and 10.22% respectively.
It has a market capitalization of $87.95M and a beta (3y monthly) value of -0.09. The earnings-per-share (ttm) stands at -$0.09. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.29% over the week and 9.68% over the month.
Analysts forecast that Homology Medicines Inc. (FIXX) will achieve an EPS of -$0.47 for the current quarter, -$0.44 for the next quarter and -$1.7 for 2023. The lowest estimate earnings-per-share for the quarter is -$0.53 while analysts give the company a high EPS estimate of -$0.41. Comparatively, EPS for the current quarter was -$0.54 a year ago. Earnings per share for the fiscal year are expected to increase by 38.20%, and -18600.00% over the next financial year. EPS should grow at an annualized rate of -9.40% over the next five years, compared to -50.70% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate Homology Medicines Inc. (FIXX) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 4 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the FIXX, a number of firms have released research notes about the stock. BTIG Research stated their Neutral rating for the stock in a research note on February 22, 2022, with the firm’s price target at $35-$29. Oppenheimer was of a view on February 22, 2022 that the stock is Perform, while Stifel gave the stock Hold rating on March 02, 2021, issuing a price target of $14. H.C. Wainwright on their part issued Buy rating on December 14, 2020.
